Direct Answer
Genomics and sequencing companies sell the instruments, reagents and services that read DNA and RNA for research, drug development and clinical testing. A large share of revenue is reagent consumables bought with each sample run.
Industry Overview
Genomics & Sequencing sits within the health care sector. The first numbers to compare across companies here are instrument installed base, consumables revenue per instrument and sequencing cost per genome. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Instrument installed base: Number of sequencers in customers' labs. Each machine generates repeat purchases of reagents, so growth in the base sets up future consumables revenue, while slowing placements signal weaker demand.
- Consumables revenue per instrument: Average reagent and kit sales generated by each sequencer. It reflects how heavily machines are used; a decline can show lower lab throughput or customers moving to cheaper platforms.
- Sequencing cost per genome: Price to read one human genome, including reagents. Falling cost expands who can afford sequencing and drives volume, but it also compresses revenue per sample unless volume grows faster.
- Gross margin: Share of revenue left after the cost of instruments, reagents and service. Reagent-heavy sales earn higher margins than instruments, so mix and manufacturing scale are the main drivers.
- Clinical share of volume: Portion of sequencing used in patient testing rather than research. Clinical use tends to be steadier and less tied to grant cycles, so a rising share can reduce funding sensitivity.
Primary Macro Drivers
- Research funding and biotech spending: Instrument purchases and reagent use depend on lab budgets, so research and biotech funding moves installed base growth and consumables sold.
- Clinical adoption of cancer and prenatal tests: When insurers pay for tests such as cancer screening and prenatal testing, clinical volume grows, which raises consumables revenue per instrument.
- Falling cost per genome: Cheaper sequencing expands what labs can afford to run, increasing volume, though lower prices per genome can pressure revenue per sample.
- Competition among sequencing platforms: Several platforms compete on cost and accuracy, so a rival's gains can shift new instrument placements and consumables share.
Major Risks
- Funding cyclicality in academic and biotech customers: Academic and biotech customers cut purchases when grants and capital markets tighten, so instrument sales and consumables slow together; watch orders and consumables per instrument.
- Competition from new platforms: New platforms can offer lower cost or longer reads, taking placements and pushing prices down; watch installed base growth and gross margin.
- Reimbursement for clinical tests: Clinical tests need insurer payment to scale, so lower rates or denials reduce volume and revenue per test; watch coverage decisions and pricing.
- Intellectual property disputes: Patent disputes can lead to damages, injunctions or licensing costs; watch legal proceedings notes in filings.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Medium |
| Regulatory Intensity | Medium |
| Industry Maturity | Growth |
| Geographic Importance | Global |
Companies Associated with Genomics & Sequencing
The SEC's Standard Industrial Classification has no code that describes genomics & sequencing as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Illumina, Inc. | Laboratory Analytical Instruments | $4.3 billion | -0.7% | 19.6% | FY 2025 |
| 10x Genomics, Inc. | Laboratory Analytical Instruments | $643 million | 5.2% | -6.8% | FY 2025 |
| Pacific Biosciences Of California, Inc. | Laboratory Analytical Instruments | $160 million | 3.9% | -341.5% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Genomics & Sequencing guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Health Care Analytics
- Generic Pharmaceuticals
- Health Care Equipment & Supplies
- Gene Therapy
- Health Care Payments Technology
- Gene Editing
- Health Care Providers & Services
- Fertility Services
Put it to work
Frequently Asked Questions
What are the main KPIs for the Genomics & Sequencing industry?
Key performance indicators for the Genomics & Sequencing industry include: Instrument installed base, Consumables revenue per instrument, Sequencing cost per genome, Gross margin, Clinical share of volume. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Genomics & Sequencing industry?
The Genomics & Sequencing industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Genomics & Sequencing industry?
The primary risks for Genomics & Sequencing companies include: Funding cyclicality in academic and biotech customers, Competition from new platforms, Reimbursement for clinical tests, Intellectual property disputes. Investors should assess each company's exposure to these factors and its track record of navigating them.